We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.12B
1-Year Est. Return 144%
This Fund
S&P 500
This Quarter Est. Return
-3.29%
1 Year Est. Return
+144%
3 Year Est. Return
+348.41%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.59B
AUM Growth
+$431M
Cap. Flow
+$681M
Cap. Flow %
26.3%
Top 10 Hldgs %
45.87%
Holding
70
New
15
Increased
18
Reduced
13
Closed
7

Top Buys

Rank Stock Value
1
GH icon
Guardant Health
GH
+$89.7M
2
NVCR icon
NovoCure
NVCR
+$72.1M
3
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$61.3M
4
AXSM icon
Axsome Therapeutics
AXSM
+$56.6M
5
APGE icon
Apogee Therapeutics
APGE
+$53.2M

Top Sells

Rank Stock Value
1
IMVT icon
Immunovant
IMVT
+$59.3M
2
GPCR icon
Structure Therapeutics
GPCR
+$23.6M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$14.9M
4
INSM icon
Insmed
INSM
+$11.4M
5
INZY
Inozyme Pharma
INZY
+$9.16M

Sector Composition

Rank Sector Weight
1 Healthcare 99.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FDMT icon
26
4D Molecular Therapeutics
FDMT
$502M
$35.4M 1.37%
2,778,107
– –
AUTL
27
Autolus Therapeutics
AUTL
$389M
$35M 1.35%
15,000,000
– –
NBIX icon
28
Neurocrine Biosciences
NBIX
$18.2B
$33.8M 1.3%
+300,000
New +$31.6M
TERN
29
DELISTED
Terns Pharmaceuticals
TERN
$30.2M 1.16%
6,000,000
+4,900,808
+446% +$31.1M
RAPT
30
DELISTED
RAPT Therapeutics
RAPT
$24.9M 0.96%
187,500
+61,930
+49% +$10.1M
BEAM icon
31
Beam Therapeutics
BEAM
$2.68B
$24.4M 0.94%
1,015,641
-301,675
-23% -$8.09M
ANAB icon
32
AnaptysBio
ANAB
$1.54B
$24.2M 0.93%
+1,345,813
New +$25.7M
OLMA icon
33
Olema Pharmaceuticals
OLMA
$977M
$23.8M 0.92%
+1,930,894
New +$19.7M
NRIX icon
34
Nurix Therapeutics
NRIX
$2.45B
$23.6M 0.91%
2,997,830
– –
ANIP icon
35
ANI Pharmaceuticals
ANIP
$1.86B
$23.2M 0.9%
400,000
-114,021
-22% -$6.58M
AMLX icon
36
Amylyx Pharmaceuticals
AMLX
$2.19B
$23.1M 0.89%
+1,259,335
New +$26.6M
BNTX icon
37
BioNTech
BNTX
$23.5B
$21.7M 0.84%
+200,000
New +$22.1M
DYN icon
38
Dyne Therapeutics
DYN
$4.15B
$21.5M 0.83%
2,403,672
-96,240
-4% -$1.04M
MRNA icon
39
Moderna
MRNA
$21.6B
$20.7M 0.8%
+200,000
New +$22.3M
SLN
40
Silence Therapeutics
SLN
$546M
$19.2M 0.74%
1,951,580
– –
PNT
41
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$18.6M 0.72%
2,781,565
– –
ZURA icon
42
Zura Bio
ZURA
$504M
$16.7M 0.64%
2,523,000
– –
ORTX
43
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$15.8M 0.61%
2,041,670
– –
EWTX icon
44
Edgewise Therapeutics
EWTX
$4.28B
$15.8M 0.61%
2,750,000
– –
PRTA icon
45
PUT
Prothena Corp
PRTA
$448M
$12.1M 0.47%
250,000
– –
NKTR icon
46
Nektar Therapeutics
NKTR
$2.39B
$11M 0.42%
1,226,667
+28,436
+2% +$274K
MORF
47
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$10.8M 0.42%
470,647
+253,895
+117% +$13.3M
AGIO icon
48
Agios Pharmaceuticals
AGIO
$2.08B
$10.5M 0.4%
+422,247
New +$11.2M
ABOS icon
49
Acumen Pharmaceuticals
ABOS
$152M
$10.4M 0.4%
2,513,044
-1,403,317
-36% -$8.67M
NUVB icon
50
Nuvation Bio
NUVB
$2.29B
$10.3M 0.4%
7,720,688
– –
1
2
3

Similar funds

AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
ACM
AKRE Capital Management Middleburg, Virginia $6.13B AUM 15.27% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
B
Barings Charlotte, North Carolina $6.19B AUM 16.5% 1-Year Est. Return

Deep Track Capital's Q3 2023 Portfolio in Review

As of Q3 2023, Deep Track Capital held 70 positions worth $2.59B, up 20% from $2.16B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Deep Track Capital deployed $681M of net new capital in Q3 2023, opening 15 new positions and adding to 18 existing holdings. Its largest new stake was NovoCure: 2,500,000 shares worth $40.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

On the sell side, the largest reduction was Immunovant, an estimated $59.3M trimmed.

  • Deep Track Capital's largest Q3 2023 buy was NovoCure: 2,500,000 shares worth $40.4M.
  • Deep Track Capital added most to Guardant Health in Q3 2023, an estimated $89.7M increase.
  • Deep Track Capital's biggest Q3 2023 reduction was Immunovant, cutting an estimated $59.3M.
  • Deep Track Capital fully exited Inozyme Pharma in Q3 2023, selling an estimated $9.16M.
  • Deep Track Capital's ten largest holdings make up 46% of its $2.59B portfolio in Q3 2023.
  • Deep Track Capital opened 15 new positions and closed 7 in Q3 2023.
  • Deep Track Capital's portfolio value rose 20% quarter-over-quarter to $2.59B.

Based on Deep Track Capital's 13F filing for Q3 2023, filed 14 Nov 2023.